Companies › Grace Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GTX-104 Nimodipine IV infusion - dihydropyridine calcium channel blocker | Ion channels | Phase 3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05995405 | GTX-104 | Phase 3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | Cardiovascular | Dec 2024 |
Cash of $14m on 2026-06-30; operating cash outflow about $13m a year; runway about 13 months at that burn, to Jul 2027
Press releases filed as 8-K in the last year:
Shenzhen Ausa Pharmed Braveheart Bio Gossamer Bio USA Mineralys Therapeutics CeleCor Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.